Biblio Discovery — Demo Discovery Service

27 hasil untuk "Dominic Pilon"

Menampilkan 1–20 · 1,49 detik · RSS

  1. Artikel Jurnal Teks lengkap

    The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States

    Maryia Zhdanava; Dominic Pilon; Isabelle Ghelerter dkk.

    The Journal of Clinical Psychiatry · 2021 · Inggris · OpenAlex Scopus

    OBJECTIVE: Estimates of prevalence and burden of treatment-resistant depression (TRD) vary widely in the literature. This study evaluated the prevalence and burden of TRD and the share of TRD in the burden of medication-treated major depressive disorder (MDD) using the most commonly accepted…

  2. Artikel Jurnal

    Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

    Dominic Pilon; Erik Muser; Patrick Lefebvre dkk.

    BMC Psychiatry, Vol. 17 No. 1 · 2017 · Inggris · DOAJ Scopus

    Abstract Background Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic that may increase adherence rates, reduce hospitalizations, and lower medical costs compared to oral atypical antipsychotics (OAAs) among schizophrenia patients. However, the impact of PP1M in…

  3. Artikel Jurnal

    Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer

    Shawn Du; Carmine Rossi; Ibrahim Khilfeh dkk.

    Journal of Health Economics and Outcomes Research, Vol. 12 No. 2 · 2025 · Inggris · DOAJ Scopus

    # Background Prostate-specific antigen (PSA) has been used as both a screening tool and a marker for treatment response for advanced prostate cancer. With the introduction of androgen receptor pathway inhibitor (ARPI)-based treatment for metastatic castration-sensitive prostate cancer (mCSPC)…

  4. Artikel Jurnal

    Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States

    Lisa Harding; Kruti Joshi; Maryia Zhdanava dkk.

    Drugs - Real World Outcomes, Vol. 11 No. 2 · 2024 · Inggris · DOAJ Scopus

    Abstract Background This study aimed to understand treatment patterns, acute healthcare use, and cost patterns among adults with treatment-resistant depression (TRD) who completed induction treatment with esketamine nasal spray in the United States (US). Per label, induction is defined as…

  5. Artikel Jurnal

    On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

    Maryia Zhdanava; Timothy Fitzgerald; Porpong Boonmak dkk.

    Journal of Dermatological Treatment, Vol. 37 No. 1 · 2026 · Inggris · DOAJ Scopus

    Objective To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.Materials and Methods This retrospective…

  6. Artikel Jurnal

    Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

    Timothy Fitzgerald; Maryia Zhdanava; Dominic Pilon dkk.

    Dermatology and Therapy, Vol. 13 No. 4 · 2023 · Inggris · DOAJ Scopus

    Abstract Background Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation. Claims data on persistence may be informative of real-world treatment outcome. This analysis…

  7. Artikel Jurnal

    A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia

    Dee Lin; Dominic Pilon; Laura Morrison dkk.

    Drugs - Real World Outcomes, Vol. 10 No. 3 · 2023 · Inggris · DOAJ Scopus

    Abstract Background Patient affordability is an important nonclinical consideration for treatment access among patients with schizophrenia. Objective This study evaluated and measured out-of-pocket (OOP) costs for antipsychotics (APs) among Medicaid beneficiaries with schizophrenia. Methods Adults…

  8. Artikel Jurnal Teks lengkap

    Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis

    Dominic Pilon; Kruti Joshi; John J. Sheehan dkk.

    PLOS ONE, Vol. 14 No. 10 · 2019 · Inggris · PLOS Scopus

    Background: Previous studies have assessed the incremental economic burden of treatment-resistant depression (TRD) versus non-treatment-resistant major depressive disorder (i.e., non-TRD MDD) in commercially-insured and Medicaid-insured patients, but none have focused on Medicare-insured patients…

    Juga tersedia di: DOAJ

  9. Artikel Jurnal Teks lengkap

    Correction: Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis

    Dominic Pilon; Kruti Joshi; John J. Sheehan dkk.

    PLOS ONE, Vol. 16 No. 4 · 2021 · Inggris · PLOS Scopus

    [This corrects the article DOI: 10.1371/journal.pone.0223255.].

    Juga tersedia di: DOAJ

  10. Artikel Jurnal

    Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA

    Manish K. Jha; Maryia Zhdanava; Aditi Shah dkk.

    Drugs - Real World Outcomes, Vol. 12 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Introduction Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes real-world mental health (MH)-related disability days and costs of patients with TRD initiated on esketamine nasal spray or…

  11. Artikel Jurnal

    Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting

    Benjamin H. Lowentritt; Carmine Rossi; Erik Muser dkk.

    Journal of Health Economics and Outcomes Research, Vol. 11 No. 2 · 2024 · Inggris · DOAJ Scopus

    # Background The use of androgen receptor signaling inhibitors, including apalutamide, in combination with androgen deprivation therapy is recommended for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). #…

  12. Artikel Jurnal

    Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate

    Gordon Brown; Sabree Burbage; Ibrahim Khilfeh dkk.

    Journal of Health Economics and Outcomes Research, Vol. 12 No. 2 · 2025 · Inggris · DOAJ Scopus

    # Background Improved clinical outcomes have been observed in patients with metastatic castration-sensitive prostate cancer (mCSPC) who experience deep prostate-specific antigen (PSA) responses after treatment with androgen receptor pathway inhibitors (ARPIs). # Objective This retrospective…

  13. Artikel Jurnal

    Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab

    Abhishek Kavati; Dominic Pilon; Benjamin Ortiz dkk.

    Allergy & Rhinology, Vol. 9 · 2018 · Inggris · DOAJ

    Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients. Objective The purpose of this study was to describe baseline characteristics of this population from a real-world dataset…

  14. Artikel Jurnal

    Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

    Maryia Zhdanava; Timothy Fitzgerald; Dominic Pilon dkk.

    Journal of Dermatological Treatment, Vol. 35 No. 1 · 2024 · Inggris · DOAJ Scopus

    Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.Methods: Adults with psoriasis initiating guselkumab…

  15. Artikel Jurnal

    Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide

    Benjamin H Lowentritt; Sabree Burbage; Ibrahim Khilfeh dkk.

    Journal of Comparative Effectiveness Research, Vol. 15 No. 2 · 2026 · Inggris · DOAJ Scopus

    Aim: There is limited real-world evidence about prostate-specific antigen (PSA) response to androgen receptor pathway inhibitor treatment in Black patientswithmetastatic castration-sensitive prostate cancer (mCSPC). This study compared PSA90 (≥90% reduction from baseline PSA level) between…

  16. Artikel Jurnal

    Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray

    Kristin Clemens; Maryia Zhdanava; Amanda Teeple dkk.

    Neurology and Therapy, Vol. 14 No. 5 · 2025 · Inggris · DOAJ Scopus

    Abstract Introduction While the literature on esketamine use in commercially insured patients with treatment-resistant depression (TRD) is growing, data on Medicaid beneficiaries remain limited. This study aimed to fill this gap by exploring characteristics of Medicaid beneficiaries with TRD who…

  17. Artikel Jurnal

    Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer

    Mehmet A. Bilen; Benjamin H. Lowentritt; Sabree Burbage dkk.

    Therapeutic Advances in Medical Oncology, Vol. 18 · 2026 · Inggris · DOAJ Scopus

    Background: Deep and rapid prostate-specific antigen (PSA) response is an important indicator to consider in treatment decision-making given its predictive value for long-term clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC). Objectives: This study compared early PSA90…